Global Irritable Bowel Syndrome Treatment

Irritable Bowel Syndrome Treatment Comprehensive Study by Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Ramosetron Hydrochloride, Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), Medical Condition (IBS-constipation, IBS-diarrhea) Players and Region - Global Market Outlook to 2027

Irritable Bowel Syndrome Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Irritable Bowel Syndrome Treatment
Irritable bowel syndrome is a gut-related functional gastrointestinal condition marked by colon muscle contractions. The large intestine is affected by irritable bowel syndrome. Irritable bowel syndrome is caused by bowel dysfunction and is more common in the elderly population. Constipation, diarrhoea, stomach pain, bowel function changes and irritation, and bloating are some of the symptoms. Because of the development of well-defined diagnostic criteria and the discovery of novel therapeutic groups by key market players, the market for irritable bowel syndrome care is growing positively. Furthermore, changes in lifestyle and eating patterns increase the prevalence of this disease, which could lead to an increase in the use of this medication and, as a result, market development.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Irritable Bowel Syndrome Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Synergy Pharmaceuticals, Inc. (United States), Sucampo Pharmaceuticals, Inc. (United States), Bausch Health Companies Inc. (Canada), Ardelyx, Inc. (United States), Astellas Pharma Inc. (Japan), Novartis AG (Switzerland), Lexicon Pharmaceuticals (United States) and Salix Pharmaceuticals (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Ironwood Pharmaceuticals, Inc. (United States), GlaxoSmithKline plc. (United Kingdom) and Allergan Plc (United States).

Segmentation Overview
AMA Research has segmented the market of Global Irritable Bowel Syndrome Treatment market by Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Ramosetron Hydrochloride and Others) and Region.



On the basis of geography, the market of Irritable Bowel Syndrome Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Irritable Bowel Syndrome Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Medical Condition, the sub-segment i.e. IBS-constipation will boost the Irritable Bowel Syndrome Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increase in Number of Pipeline Drugs

Market Growth Drivers:
Rise in Geriatric Population and Increase in the Prevalence of Gastrointestinal Disorders

Challenges:
Higher Competition among the Key Players in terms of Pricing

Restraints:
Lack of Specific Treatment which Treats all the Symptoms of Disorder

Opportunities:
Untapped Opportunities in Developing Economies and Increased Awareness about Available Treatment among the Patients

Market Leaders and their expansionary development strategies
In May 2020, AbbVie acquires Allergan This merger brought together AbbVie's Linzess (linaclotide) and Allergan's Viberzi (eluxadoline), two leading prescription drugs for IBS with constipation. This deal solidified AbbVie's position as a major player in the IBS marke
In Jan 2019, Ironwood Pharmaceuticals and AstraZeneca received marketing approval for Linzess in China with an aim to strengthen its position in the market.


Key Target Audience
New Entrants/Investors, Venture Capitalists and Private Equity Firms, Analysts and Strategic Business Planners, Government Regulatory and Research Organizations, End-Use Industries and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Lubiprostone
  • Linaclotide
  • Eluxadoline
  • Rifaximin
  • Ramosetron Hydrochloride
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Medical Condition
  • IBS-constipation
  • IBS-diarrhea

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Geriatric Population
      • 3.2.2. Increase in the Prevalence of Gastrointestinal Disorders
    • 3.3. Market Challenges
      • 3.3.1. Higher Competition among the Key Players in terms of Pricing
    • 3.4. Market Trends
      • 3.4.1. Increase in Number of Pipeline Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Irritable Bowel Syndrome Treatment, by Type, Distribution Channel, Medical Condition and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Irritable Bowel Syndrome Treatment (Value)
      • 5.2.1. Global Irritable Bowel Syndrome Treatment by: Type (Value)
        • 5.2.1.1. Lubiprostone
        • 5.2.1.2. Linaclotide
        • 5.2.1.3. Eluxadoline
        • 5.2.1.4. Rifaximin
        • 5.2.1.5. Ramosetron Hydrochloride
        • 5.2.1.6. Others
      • 5.2.2. Global Irritable Bowel Syndrome Treatment by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Online Pharmacies
        • 5.2.2.3. Retail Pharmacies
      • 5.2.3. Global Irritable Bowel Syndrome Treatment by: Medical Condition (Value)
        • 5.2.3.1. IBS-constipation
        • 5.2.3.2. IBS-diarrhea
      • 5.2.4. Global Irritable Bowel Syndrome Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Irritable Bowel Syndrome Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Synergy Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sucampo Pharmaceuticals, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bausch Health Companies Inc. (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ardelyx, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Astellas Pharma Inc. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lexicon Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Salix Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Irritable Bowel Syndrome Treatment Sale, by Type, Distribution Channel, Medical Condition and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Irritable Bowel Syndrome Treatment (Value)
      • 7.2.1. Global Irritable Bowel Syndrome Treatment by: Type (Value)
        • 7.2.1.1. Lubiprostone
        • 7.2.1.2. Linaclotide
        • 7.2.1.3. Eluxadoline
        • 7.2.1.4. Rifaximin
        • 7.2.1.5. Ramosetron Hydrochloride
        • 7.2.1.6. Others
      • 7.2.2. Global Irritable Bowel Syndrome Treatment by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Online Pharmacies
        • 7.2.2.3. Retail Pharmacies
      • 7.2.3. Global Irritable Bowel Syndrome Treatment by: Medical Condition (Value)
        • 7.2.3.1. IBS-constipation
        • 7.2.3.2. IBS-diarrhea
      • 7.2.4. Global Irritable Bowel Syndrome Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Irritable Bowel Syndrome Treatment: by Type(USD Million)
  • Table 2. Irritable Bowel Syndrome Treatment Lubiprostone , by Region USD Million (2016-2021)
  • Table 3. Irritable Bowel Syndrome Treatment Linaclotide , by Region USD Million (2016-2021)
  • Table 4. Irritable Bowel Syndrome Treatment Eluxadoline , by Region USD Million (2016-2021)
  • Table 5. Irritable Bowel Syndrome Treatment Rifaximin , by Region USD Million (2016-2021)
  • Table 6. Irritable Bowel Syndrome Treatment Ramosetron Hydrochloride , by Region USD Million (2016-2021)
  • Table 7. Irritable Bowel Syndrome Treatment Others , by Region USD Million (2016-2021)
  • Table 8. Irritable Bowel Syndrome Treatment: by Distribution Channel(USD Million)
  • Table 9. Irritable Bowel Syndrome Treatment Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 10. Irritable Bowel Syndrome Treatment Online Pharmacies , by Region USD Million (2016-2021)
  • Table 11. Irritable Bowel Syndrome Treatment Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 12. Irritable Bowel Syndrome Treatment: by Medical Condition(USD Million)
  • Table 13. Irritable Bowel Syndrome Treatment IBS-constipation , by Region USD Million (2016-2021)
  • Table 14. Irritable Bowel Syndrome Treatment IBS-diarrhea , by Region USD Million (2016-2021)
  • Table 15. South America Irritable Bowel Syndrome Treatment, by Country USD Million (2016-2021)
  • Table 16. South America Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 17. South America Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 18. South America Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 19. Brazil Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 20. Brazil Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 21. Brazil Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 22. Argentina Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 23. Argentina Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 24. Argentina Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 25. Rest of South America Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 26. Rest of South America Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 27. Rest of South America Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 28. Asia Pacific Irritable Bowel Syndrome Treatment, by Country USD Million (2016-2021)
  • Table 29. Asia Pacific Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 30. Asia Pacific Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 31. Asia Pacific Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 32. China Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 33. China Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 34. China Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 35. Japan Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 36. Japan Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 37. Japan Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 38. India Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 39. India Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 40. India Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 41. South Korea Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 42. South Korea Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 43. South Korea Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 44. Taiwan Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 45. Taiwan Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 46. Taiwan Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 47. Australia Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 48. Australia Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 49. Australia Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 53. Europe Irritable Bowel Syndrome Treatment, by Country USD Million (2016-2021)
  • Table 54. Europe Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 55. Europe Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 56. Europe Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 57. Germany Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 58. Germany Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 59. Germany Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 60. France Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 61. France Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 62. France Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 63. Italy Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 64. Italy Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 65. Italy Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 66. United Kingdom Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 67. United Kingdom Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 68. United Kingdom Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 69. Netherlands Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 70. Netherlands Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 71. Netherlands Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 72. Rest of Europe Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 73. Rest of Europe Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 74. Rest of Europe Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 75. MEA Irritable Bowel Syndrome Treatment, by Country USD Million (2016-2021)
  • Table 76. MEA Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 77. MEA Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 78. MEA Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 79. Middle East Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 80. Middle East Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 81. Middle East Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 82. Africa Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 83. Africa Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 84. Africa Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 85. North America Irritable Bowel Syndrome Treatment, by Country USD Million (2016-2021)
  • Table 86. North America Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 87. North America Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 88. North America Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 89. United States Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 90. United States Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 91. United States Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 92. Canada Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 93. Canada Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 94. Canada Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 95. Mexico Irritable Bowel Syndrome Treatment, by Type USD Million (2016-2021)
  • Table 96. Mexico Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 97. Mexico Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2016-2021)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Irritable Bowel Syndrome Treatment: by Type(USD Million)
  • Table 108. Irritable Bowel Syndrome Treatment Lubiprostone , by Region USD Million (2022-2027)
  • Table 109. Irritable Bowel Syndrome Treatment Linaclotide , by Region USD Million (2022-2027)
  • Table 110. Irritable Bowel Syndrome Treatment Eluxadoline , by Region USD Million (2022-2027)
  • Table 111. Irritable Bowel Syndrome Treatment Rifaximin , by Region USD Million (2022-2027)
  • Table 112. Irritable Bowel Syndrome Treatment Ramosetron Hydrochloride , by Region USD Million (2022-2027)
  • Table 113. Irritable Bowel Syndrome Treatment Others , by Region USD Million (2022-2027)
  • Table 114. Irritable Bowel Syndrome Treatment: by Distribution Channel(USD Million)
  • Table 115. Irritable Bowel Syndrome Treatment Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 116. Irritable Bowel Syndrome Treatment Online Pharmacies , by Region USD Million (2022-2027)
  • Table 117. Irritable Bowel Syndrome Treatment Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 118. Irritable Bowel Syndrome Treatment: by Medical Condition(USD Million)
  • Table 119. Irritable Bowel Syndrome Treatment IBS-constipation , by Region USD Million (2022-2027)
  • Table 120. Irritable Bowel Syndrome Treatment IBS-diarrhea , by Region USD Million (2022-2027)
  • Table 121. South America Irritable Bowel Syndrome Treatment, by Country USD Million (2022-2027)
  • Table 122. South America Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 123. South America Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 124. South America Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 125. Brazil Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 126. Brazil Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 127. Brazil Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 128. Argentina Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 129. Argentina Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 130. Argentina Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 131. Rest of South America Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 132. Rest of South America Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 133. Rest of South America Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 134. Asia Pacific Irritable Bowel Syndrome Treatment, by Country USD Million (2022-2027)
  • Table 135. Asia Pacific Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 136. Asia Pacific Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 137. Asia Pacific Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 138. China Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 139. China Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 140. China Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 141. Japan Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 142. Japan Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 143. Japan Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 144. India Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 145. India Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 146. India Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 147. South Korea Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 148. South Korea Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 149. South Korea Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 150. Taiwan Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 151. Taiwan Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 152. Taiwan Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 153. Australia Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 154. Australia Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 155. Australia Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 156. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 157. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 158. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 159. Europe Irritable Bowel Syndrome Treatment, by Country USD Million (2022-2027)
  • Table 160. Europe Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 161. Europe Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 162. Europe Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 163. Germany Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 164. Germany Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 165. Germany Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 166. France Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 167. France Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 168. France Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 169. Italy Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 170. Italy Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 171. Italy Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 172. United Kingdom Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 173. United Kingdom Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 174. United Kingdom Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 175. Netherlands Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 176. Netherlands Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 177. Netherlands Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 178. Rest of Europe Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 179. Rest of Europe Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 180. Rest of Europe Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 181. MEA Irritable Bowel Syndrome Treatment, by Country USD Million (2022-2027)
  • Table 182. MEA Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 183. MEA Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 184. MEA Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 185. Middle East Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 186. Middle East Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 187. Middle East Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 188. Africa Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 189. Africa Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 190. Africa Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 191. North America Irritable Bowel Syndrome Treatment, by Country USD Million (2022-2027)
  • Table 192. North America Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 193. North America Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 194. North America Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 195. United States Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 196. United States Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 197. United States Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 198. Canada Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 199. Canada Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 200. Canada Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 201. Mexico Irritable Bowel Syndrome Treatment, by Type USD Million (2022-2027)
  • Table 202. Mexico Irritable Bowel Syndrome Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 203. Mexico Irritable Bowel Syndrome Treatment, by Medical Condition USD Million (2022-2027)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Irritable Bowel Syndrome Treatment: by Type USD Million (2016-2021)
  • Figure 5. Global Irritable Bowel Syndrome Treatment: by Distribution Channel USD Million (2016-2021)
  • Figure 6. Global Irritable Bowel Syndrome Treatment: by Medical Condition USD Million (2016-2021)
  • Figure 7. South America Irritable Bowel Syndrome Treatment Share (%), by Country
  • Figure 8. Asia Pacific Irritable Bowel Syndrome Treatment Share (%), by Country
  • Figure 9. Europe Irritable Bowel Syndrome Treatment Share (%), by Country
  • Figure 10. MEA Irritable Bowel Syndrome Treatment Share (%), by Country
  • Figure 11. North America Irritable Bowel Syndrome Treatment Share (%), by Country
  • Figure 12. Global Irritable Bowel Syndrome Treatment share by Players 2021 (%)
  • Figure 13. Global Irritable Bowel Syndrome Treatment share by Players (Top 3) 2021(%)
  • Figure 14. Global Irritable Bowel Syndrome Treatment share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 18. Synergy Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Synergy Pharmaceuticals, Inc. (United States) Revenue: by Geography 2021
  • Figure 20. Sucampo Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Sucampo Pharmaceuticals, Inc. (United States) Revenue: by Geography 2021
  • Figure 22. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 23. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2021
  • Figure 24. Ardelyx, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Ardelyx, Inc. (United States) Revenue: by Geography 2021
  • Figure 26. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Astellas Pharma Inc. (Japan) Revenue: by Geography 2021
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 30. Lexicon Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Lexicon Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 32. Salix Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 33. Salix Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 34. Global Irritable Bowel Syndrome Treatment: by Type USD Million (2022-2027)
  • Figure 35. Global Irritable Bowel Syndrome Treatment: by Distribution Channel USD Million (2022-2027)
  • Figure 36. Global Irritable Bowel Syndrome Treatment: by Medical Condition USD Million (2022-2027)
  • Figure 37. South America Irritable Bowel Syndrome Treatment Share (%), by Country
  • Figure 38. Asia Pacific Irritable Bowel Syndrome Treatment Share (%), by Country
  • Figure 39. Europe Irritable Bowel Syndrome Treatment Share (%), by Country
  • Figure 40. MEA Irritable Bowel Syndrome Treatment Share (%), by Country
  • Figure 41. North America Irritable Bowel Syndrome Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Synergy Pharmaceuticals, Inc. (United States)
  • Sucampo Pharmaceuticals, Inc. (United States)
  • Bausch Health Companies Inc. (Canada)
  • Ardelyx, Inc. (United States)
  • Astellas Pharma Inc. (Japan)
  • Novartis AG (Switzerland)
  • Lexicon Pharmaceuticals (United States)
  • Salix Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Ironwood Pharmaceuticals, Inc. (United States) , GlaxoSmithKline plc. (United Kingdom) , Allergan Plc (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 215 Pages 68 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Irritable Bowel Syndrome Treatment Quantitative research analysis
Global Irritable Bowel Syndrome Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Synergy Pharmaceuticals, Inc. (United States), Sucampo Pharmaceuticals, Inc. (United States), Bausch Health Companies Inc. (Canada), Ardelyx, Inc. (United States), Astellas Pharma Inc. (Japan), Novartis AG (Switzerland), Lexicon Pharmaceuticals (United States) and Salix Pharmaceuticals (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase in Number of Pipeline Drugs" is seen as one of major influencing trends for Irritable Bowel Syndrome Treatment Market during projected period 2021-2027.
The Irritable Bowel Syndrome Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Irritable Bowel Syndrome Treatment Report?

Have a Query? Click Here

Other Related Reports

Cancer Test Comprehensive Study by Type (Laboratory Tests, Genetic Tests, Imaging, Endoscopy), Application (Bladder Cancer Test, Breast Cancer Test, Cervical Cancer Test, Colorectal (Colon) Cancer Te...
$ 3650
Dermatological Therapeutics Comprehensive Study by Type (Anti-infectives , Corticosteroids, Anti Psoriasis, Anti-acne , Others), Application (Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, Alopec...
$ 3750
Thyroid Cancer Treatment Comprehensive Study by Type (Surgery, Iodine Therapy, External Radiotherapy, Thyroxin Treatment, Chemotherapy, Drugs), Application (Hospitals, Oncology centers, Hospital Phar...
$ 3650
Urinary Tract Cancer Comprehensive Study by Type (Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Others), Diagnosis Technique (Cytoscopy, Urine Analyses, Biopsy, Imaging Test (Compute...
$ 3750
Mesenchymal Stem Cells Comprehensive Study by Type (MSC-BM, MSC-UC, MSC-AT, Others), Application (Cell Differentiation and Gene Regulation, Gene Therapy and Transplantation, Cell-based Screening Assa...
$ 3500
Retinoblastoma Treatment Comprehensive Study by Type (Alkylating Agents, Antimetabolites, Microtubule Inhibitors, Cytotoxic Antibiotics, Topoisomerase Inhibitors), Application (Intraocular Retinoblas...
$ 3750